No Data
No Data
Is Denali Therapeutics Inc. (NASDAQ:DNLI) Trading At A 31% Discount?
Key Insights Denali Therapeutics' estimated fair value is US$33.10 based on 2 Stage Free Cash Flow to Equity Denali Therapeutics is estimated to be 31% undervalued based on current share price of
Denali Therapeutics Price Target Raised to $29.00/Share From $28.00 by JP Morgan
Denali Therapeutics Price Target Raised to $29.00/Share From $28.00 by JP
Denali Therapeutics Is Maintained at Overweight by JP Morgan
Denali Therapeutics Is Maintained at Overweight by JP
Denali Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/10/2024 37.83% JP Morgan $28 → $29 Maintains Overweight 05/08/2024 351.52% HC Wainwright & Co. $95 → $9
J.P. Morgan Maintains Denali Therapeutics(DNLI.US) With Buy Rating, Announces Target Price $29
J.P. Morgan analyst Jessica Fye maintains $Denali Therapeutics(DNLI.US)$ with a buy rating, and sets the target price at $29.According to TipRanks data, the analyst has a success rate of 54.0% and a
Buy Rating Affirmed for Denali Therapeutics Amid Promising ETV Advancements and Strategic Positioning